{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:08Z","timestamp":1777374428699,"version":"3.51.4"},"reference-count":7,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jcf.2024.02.014","type":"journal-article","created":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T23:39:01Z","timestamp":1709509141000},"page":"368-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility"],"prefix":"10.1016","volume":"23","author":[{"given":"Jaime L.","family":"Rubin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Kreindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jcf.2024.02.014_bib0001","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jcf.2024.02.014_bib0002","first-page":"00066","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"S1569-1993","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.014_bib0003","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"S203","key":"10.1016\/j.jcf.2024.02.014_bib0004","article-title":"Achieving equitable access to CFTR modulators: every patient in every country","volume":"22","author":"Guo","year":"2023","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.02.014_bib0005","unstructured":"Cystic Fibrosis Foundation. Restore CFTR: exploring treatments for rare and nonsense mutations [Internet] 2023 Available from: https:\/\/www.cff.org\/research-clinical-trials\/restore-cftr-exploring-treatments-rare-and-nonsense-mutations#:~:text=Around%207%20percent%20of%20people,underlying%20cause%20of%20their%20diseasee. Accessed 09\/20\/2023."},{"key":"10.1016\/j.jcf.2024.02.014_bib0006","unstructured":"J.P. Morgan Healthcare conference [Internet] 2023 Available from: https:\/\/investors.vrtx.com\/static-files\/262d3f01-23e3-4184-b42a-1033357661e0. Accessed 26 January 2024."},{"key":"10.1016\/j.jcf.2024.02.014_bib0007","unstructured":"Vertex Pharmaceuticals. Our approved medicines [Internet]. 2023 Available from: https:\/\/www.vrtx.com\/medicines\/our-approved-medicines\/. Accessed 21 Dec 2023."}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T08:23:40Z","timestamp":1772353420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1569199324000286"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.02.014","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}